Chronic administration of olanzapine induces metabolic and food intake alterations: A mouse model of the atypical antipsychotic-associated adverse effects

Psychopharmacology

Volumn 186, Issue 4, 2006, Pages 561-571

  Coccurello, R ^a,b   Caprioli, A ^b   Ghirardi, O ^b   Conti, R ^b   Ciani, B ^b   Daniele, S ^b   Bartolomucci, A ^a   Moles, A ^a  

^a CNR   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

Antipsychotics; Calorimetry; Metabolic syndrome; Mouse model; Olanzapine; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FATTY ACID; GLUCOSE; INSULIN; OLANZAPINE; SUCROSE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BODY FAT; BODY WEIGHT; CALORIMETRY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DIET; DOSE RESPONSE; DRUG MEGADOSE; ENERGY EXPENDITURE; FEEDING; FEMALE; FOOD INTAKE; HABITUATION; HYPERINSULINEMIA; LOCOMOTION; MALE; METABOLIC DISORDER; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PALATABILITY; PRIORITY JOURNAL; RESPIRATORY QUOTIENT; SCHIZOPHRENIA; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY WEIGHT; CALORIMETRY, INDIRECT; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENERGY METABOLISM; FATTY ACIDS; FEMALE; INFUSION PUMPS, IMPLANTABLE; INSULIN; INTRA-ABDOMINAL FAT; LIPID METABOLISM; MICE; MOTOR ACTIVITY; OBESITY; TIME FACTORS; TRIGLYCERIDES;

EID: 33744956920     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0368-5     Document Type: Article

References (88)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
2. Arjona AA, Zhang SX, Adamson B, Wurtman RJ (2004) An animal model of antipsychotic-induced weight gain. Behav Brain Res 152:121-127
3. Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM, Navarro MA, San L (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65:1335-1342
4. Atmaca M, Kuloglu M, Tezcan E, Ustung B (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64:598-604
5. Baptista T, Parada M, Hernandez L (1987) Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27:399-405
6. Baptista T, Kin NM, Beaulieu S, de Baptista EA (2002a) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205-219
7. Baptista T, Araujo de Baptista E, Ying Kin NM, Beaulieu S, Walker D, Joober R, Lalonde J, Richard D (2002b) Comparative effects of the antipsychotics sulpiride or risperidone in rats. I. Bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res 957:144-151
8. Baptista T, Lacruz A, Paez X, Hernandez L, Beaulieu S (2002c) The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved? Eur J Pharmacol 447:91-98
9. Baptista T, de Baptista EA, Lalonde J, Plamondon J, Kin NM, Beaulieu S, Joober R, Richard D (2004) Comparative effects of the antipsychotics sulpiride and risperidone in female rats on energy balance, body composition, fat morphology and macronutrient selection. Prog Neuropsychopharmacol Biol Psychiatry 28:1305-1311
10. Blundell JE (1986) Serotonin manipulations and the structure of feeding behaviour. Appetite 7:39-56(Suppl)
11. Bosello O, Zamboni M (2000) Visceral obesity and metabolic syndrome. Obes Rev 1:47-56
12. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand J (1998) Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 3:76-80
13. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, Foreman MM, Lucaites VL, Calligaro DO (1999) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107-122
14. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD, Shofer JB, Fish BE, Knopp RH, Kahn SE (2004) Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53:2087-2094
15. Casey DE, Zorn SH (2001) The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 62(Suppl 7):4-10
16. Chen TY, Dull SL, Huang CC, Lin TB, Kuo DY (2001) Evidence for the involvement of dopamine D(1) and D(2) receptors in mediating the decrease of food intake during repeated treatment with amphetamine. J Biomed Sci 8:462-466
17. Chiu JA, Franklin RB (1996) Analysis and pharmacokinetics of olanzapine (LY 170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. J Pharm Biomed Anal 14:609-615
18. Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH, Kahn SE (2002) The concurrent accumulation of intraabdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51:1005-1015
19. Cnop M, Havel PJ, Utzschneider KM, Carr DR, Sinha MK, Bovko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459-469
20. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181:80-89
21. Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, Allison DB (2005) Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes 29:607-614
22. De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication (Epub ahead of print). Schizophr Res. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db= pubmed&dopt=Abstract&list_uids=16481149&query_hl= 6& itool=pubmed_docsum. Accessed on 13 Feb 2002
23. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (1999) SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 38:1195-1205
24. Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (2000) Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. Brain Res 865:85-90
25. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
26. Felber JP, Ferrannini E, Golay A, Meyer HU, Theibaud D, Curchod B, Maeder E, Jequier E, DeFronzo RA (1987) Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 36:1341-1350
27. Fell MJ, Marshall KM, Williams J, Neill JC (2004) Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol 18:149-155
28. Fertig MK, Brooks VG, Shelton PS, English CW (1998) Hyperglycemia associated with olanzapine. J Clin Psychiatry 59:687-689
29. Gan SK, Kriketos AD, Poynten AM, Furler SM, Thompson CH, Kraegen EW et al (2003) Insulin action, regional fat, and myocyte lipid: altered relationships with increased adiposity. Obes Res 11:1295-1305
30. Gilbert DB, Cooper SJ (1985) Analysis of dopamine D1 and D2 receptor involvement in d- and 1-amphetamine-induced anorexia in rats. Brain Res Bull 15:385-389
31. Goudie AJ, Smith JA, Halford JC (2002) Characterization of olanzapine-induced weight gain in rats. J Psychopharmacol 16:291-296
32. Goudie AJ, Halford JC, Dovey TM, Cooper GD, Neill JC (2003) H (1)-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:2209
33. Grundy SM (1999) Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 83:25F-29F
34. Hartfield AW, Moore NA, Clifton PG (2003a) Serotonergic and histaminergic mechanisms involved in intralipid drinking? Pharmacol Biochem Behav 76:251-258
35. Hartfield AW, Moore NA, Clifton PG (2003b) Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat. Psychopharmacology (Berl) 167:115-122
36. Hartfield AW, Moore NA, Clifton PG (2005) Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats (Epub ahead of print). Neuropsychopharmacology. DOI:10.1038/sj.npp.1300949
37. Hewitt KN, Lee MD, Dourish CT, Clifton PG (2002) Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacol Biochem Behav 71:691-700
38. Jones B, Basson B, Walker D et al (2001) Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 62(Suppl 2):41-44
39. Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DN (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berl) 182:220-231
40. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928
41. Kapur S, Vanderspek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631
42. Kaur G, Kulkarni SK (2002) Studies on modulation of feeding behavior by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry 26:277-285
43. Kirk SL, Neill JC, Jones DN, Reynolds GP (2004) Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol 505:253-254
44. Kobayashi K (2005) Adipokines: therapeutic targets for metabolic syndrome. Curr Drug Targets 6:525-529
45. Kolterman OG, Insel J, Saekow M, Olefsky JM (1980) Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest 65:1272-1284
46. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M et al (1999) Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156:312-314
47. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526
48. Kuo DY (2002) Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats. J Biomed Sci 9:126-132
49. Lucki K, Kreider MS, Simansky KJ (1988) Reduction of feeding behavior by the serotonin uptake inhibitor sertraline. Psychopharmacology (Berl) 96:289-295
50. Macor C, Ruggeri A, Mazzonetto P, Federspil G, Cobelli C, Vettor R (1997) Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity. Metabolism 46:123-129
51. Magrani J, de Castro e Silva E, Varjao B, Duarte G, Ramos AC, Athanazio R, Barbetta M, Luz P, Fregoneze JB (2004) Histaminergic H1 and H2 receptors located within the ventromedial hypothalamus regulate food and water intake in rats. Pharmacol Biochem Behav 79:189-198
52. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T (2001a) Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes 50:385-391
53. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T (2001b) Central infusion of histamine reduces fat accumulation and upregulates UCP family in leptin-resistant obese mice. Diabetes 50:376-384
54. Masaki T, Chiba S, Yasuda T, Noguchi H, Kakuma T, Watanabe T, Sakata T, Yoshimatsu H (2004) Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 53:2250-2260
55. Mattiuz E, Franklin R, Gillespie T, Murphy A, Bernstein J, Chiu A, Hotten T, Kassahun K (1997) Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab Dispos 25:573-583
56. McIntyre RS, McCann SM, Kennedy SH (2001) Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 46:273-281
57. Melkersson KI, Hulting AL, Brismar KE (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61:742-749
58. Mercer LP, Kelley DS, Humphries LL, Dunn JD (1994) Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats. J Nutr 124:1029-1036
59. Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1-17
60. Morimoto T, Yamamoto Y, Mobarakeh JI, Yanai K, Watanabe T, Watanabe T, Yamatodani A (1999) Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav 67:679-683
61. Newcomer JW (2004) Metabolic risk during antipsychotic treatment. Clin Ther 26:1936-1946
62. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19:1-93
63. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993) Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
64. Nordstrom AL, Nyberg S, Olsson H, Farde L (1998) Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch Gen Psychiatry 55:283-284
65. Ookuma K, Sakata T, Fukagawa K, Yoshimatsu H, Kurokawa M, Machidori H, Fujimoto K (1993) Neuronal histamine in the hypothalamus suppresses food intake in rats. Brain Res 628:235-242
66. Ota M, Mori K, Nakashina A, Kaneko YS, Fujiwara K, Itoh M, Nagasaka A, Ota A (2002) Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. Clin Exp Pharmacol Physiol 29:980-989
67. Palanza P (2001) Animal models of anxiety and depression: how are females different? Neurosci Biobehav Rev 25:219-233
68. Pouzet B, Mow T, Kreilgaard M, Velschow S (2002) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75:133-140
69. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607
70. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39
71. Sahakian BJ, Burdess C, Luckhurst H, Trayhurn P (1982) Hyperactivity and obesity: the interaction of social isolation and cafeteria feeding. Physiol Behav 28:117-124
72. Sakata T, Yoshimatsu H, Kurokawa M (1997) Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition 13:403-411
73. Schutz Y, Tremblay A, Weinsier RL, Nelson KM (1992) Role of fat oxidation in the long-term stabilization of body weight in obese women. Am J Clin Nutr 55:670-674
74. Schwartz MW, Sipols AJ, Marks JL, Sanacora G, White JD, Scheurink A, Kahn SE, Baskin DG, Woods SC, Figlewicz DP (1992) Inhibition of hypothalamic neuropeptide Y gene expression by insulin. Endocrinology 130:3608-3616
75. Shor-Posner G, Grinker JA, Marinescu C, Brown O, Leibowitz SF (1986) Hypothalamic serotonin in the control of meal patterns and macronutrient selection. Brain Res Bull 17:663-671
76. Simpson GM (2005) Atypical antipsychotics and the burden of disease. Am J Manag Care 11:S235-S241
77. Sipols AJ, Baskin DG, Schwartz MW (1995) Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 44:147-151
78. Stahl SM, Shayegan DK (2003) The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 64:6-12
79. Taylor DM, McAskill R (2000) Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 101:416-432
80. Theisen F, Linden A, Konig I et al (2003) Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 110:111-121
81. Valzelli L (1973) The "isolation syndrome" in mice. Psychopharmacologia 31:305-320
82. Verdich C, Toubro S, Buemann B, Holst JJ, Bulow J, Simonsen L, Sondergaard SB, Christensen NJ, Astrup A (2001) Leptin levels are associated with fat oxidation and dietary-induced weight loss in obesity. Obes Res 9:452-461
83. Wetterling T (2001) Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24:59-73
84. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR (1999) Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358-363
85. Wurtman JJ, Wurtman RJ (1979) Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats. Life Sci 24:895-903
86. Yamada K, Ohki-Hamazaki H, Wada K (2000) Differential effects of social isolation upon body weight, food consumption, and responsiveness to novel and social environment in bombesin receptor subtype-3 (BRS-3) deficient mice. Physiol Behav 68:555-561
87. Yoshimatsu H, Itateyama E, Kondou S, Tajima D, Himeno K, Hidaka S, Kurokawa M, Sakata T (1999) Hypothalamic neuronal histamine as a target of leptin in feeding behavior. Diabetes 48:2286-2291
88. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Br J Psychiatry 184:58-62